JP2025510777A5 - - Google Patents
Info
- Publication number
- JP2025510777A5 JP2025510777A5 JP2024556411A JP2024556411A JP2025510777A5 JP 2025510777 A5 JP2025510777 A5 JP 2025510777A5 JP 2024556411 A JP2024556411 A JP 2024556411A JP 2024556411 A JP2024556411 A JP 2024556411A JP 2025510777 A5 JP2025510777 A5 JP 2025510777A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- acid sequence
- utr
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323748P | 2022-03-25 | 2022-03-25 | |
| US63/323,748 | 2022-03-25 | ||
| US202263405142P | 2022-09-09 | 2022-09-09 | |
| US63/405,142 | 2022-09-09 | ||
| US202263419924P | 2022-10-27 | 2022-10-27 | |
| US63/419,924 | 2022-10-27 | ||
| PCT/US2023/016192 WO2023183550A2 (en) | 2022-03-25 | 2023-03-24 | Messenger ribonucleic acids with extended half-life |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510777A JP2025510777A (ja) | 2025-04-15 |
| JP2025510777A5 true JP2025510777A5 (enExample) | 2026-03-31 |
Family
ID=86330236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556411A Pending JP2025510777A (ja) | 2022-03-25 | 2023-03-24 | 半減期が延長されたメッセンジャーリボ核酸 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250313830A1 (enExample) |
| EP (1) | EP4499850A2 (enExample) |
| JP (1) | JP2025510777A (enExample) |
| CN (1) | CN119234042A (enExample) |
| TW (1) | TW202345870A (enExample) |
| WO (1) | WO2023183550A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118542697B (zh) * | 2024-05-13 | 2025-07-08 | 广州万方健医药有限公司 | 性生活使用后的避孕套在同时采集和/或检测男性和女性生殖道病原体中的应用 |
| WO2026085234A1 (en) * | 2024-10-18 | 2026-04-23 | Modernatx, Inc. | 3' untranslated region sequences for extending messenger ribonucleic acids half-life |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017191274A2 (en) * | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| CA3174553A1 (en) * | 2020-03-05 | 2021-09-10 | Flagship Pioneering Innovations Vi, Llc | Host defense suppressing methods and compositions for modulating a genome |
| EP4158005A1 (en) * | 2020-06-01 | 2023-04-05 | ModernaTX, Inc. | Phenylalanine hydroxylase variants and uses thereof |
| WO2021248008A1 (en) * | 2020-06-05 | 2021-12-09 | Innovation Pharmaceuticals Inc. | Arylamide compounds for treatment and prevention of viral infections |
| EP4168556A2 (en) * | 2020-06-23 | 2023-04-26 | ModernaTX, Inc. | Lnp compositions comprising mrna therapeutics with extended half-life |
-
2023
- 2023-03-24 US US18/849,675 patent/US20250313830A1/en active Pending
- 2023-03-24 JP JP2024556411A patent/JP2025510777A/ja active Pending
- 2023-03-24 TW TW112111277A patent/TW202345870A/zh unknown
- 2023-03-24 WO PCT/US2023/016192 patent/WO2023183550A2/en not_active Ceased
- 2023-03-24 CN CN202380041777.XA patent/CN119234042A/zh active Pending
- 2023-03-24 EP EP23722467.0A patent/EP4499850A2/en active Pending